AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7313578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IM and IV administration of ampicillin
Number of subjects: 44
Study 31568281 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative magnetic resonance imaging for flap tissue planning
Number of subjects: 62
Study 31568281 — intervention group
Group type: COMPARATOR
Intervention: External Doppler ultrasonography for flap planning
Number of subjects: 62
Study 31568281 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative vascular mapping by magnetic resonance imaging
Number of subjects: 62
Study 31568281 — intervention group
Group type: COMPARATOR
Intervention: External Doppler ultrasonography
Number of subjects: 62
Study 28434473 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at LIV3
Number of subjects: 97
Study 28434473 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at LI4
Number of subjects: 97
Study 28434473 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure
Number of subjects: 97
Study 25828037 — intervention group
Group type: EXPERIMENTAL
Intervention: Small particle hyaluronic acid plus lidocaine (SPHAL)
Number of subjects: 0
Study 25828037 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 23512273 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy intervention for body image-related concerns
Number of subjects: 150
Study 21163921 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants in STXBP5 (rs1039084)
Number of subjects: 1366
Study 21163921 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants in VWF (rs1063856)
Number of subjects: 1366
Study 21163921 — intervention group
Group type: COMPARATOR
Intervention: Variants in SCARA5, STAB2, STX2, TC2N, and CLEC4M
Number of subjects: 1366
Study 19489429 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual reminiscence therapy (5-6 weekly sessions, 30-60 minutes each)
Number of subjects: 80
Study 19489429 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 80
Study 17823443 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (54% carbohydrate, 16% protein, 30% fat, 7% saturated fat)
Number of subjects: 131
Study 17823443 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate diet (39%)
Number of subjects: 131
Study 17823443 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (26%) and low-saturated-fat (9%) diet
Number of subjects: 131
Study 17823443 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (26%) and high-saturated-fat (15%) diet
Number of subjects: 131
Study 17823443 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute weight loss diet (−1103.0 ± 216.5 kcal/d)
Number of subjects: 131
Study 17823443 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization at reduced weight
Number of subjects: 131
Study 15483468 — intervention group
Group type: COMPARATOR
Intervention: Recombinant gp120 HIV vaccine (AIDSVAX B/B)
Number of subjects: 5417
Study 11213870 — intervention group
Group type: EXPERIMENTAL
Intervention: Abalon (soy protein [50 g/day] with high levels of isoflavones [minimum 165 mg/day] and cotyledon fiber [20 g/day])
Number of subjects: 20
Study 11213870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (casein [50 g/day] and cellulose [20 g/day])
Number of subjects: 20
Study 9669254 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaz‐Schatz stent implantation
Number of subjects: 110
Study 9669254 — intervention group
Group type: COMPARATOR
Intervention: PTCA (balloon angioplasty)
Number of subjects: 110
Study 8675565 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS (1 microgram/kg, sc) + GHRH (1 microgram/kg, iv)
Number of subjects: 24
Study 8675565 — intervention group
Group type: COMPARATOR
Intervention: Control test (no SMS) + GHRH (1 microgram/kg, iv)
Number of subjects: 24
Study 2802549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (1,000 mg single dose)
Number of subjects: 89
Study 2802549 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (250 mg three times a day for 7 days)
Number of subjects: 89
Study 768913 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (600 mg/day)
Number of subjects: 0
Study 768913 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 28723821 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance wristband
Number of subjects: 179
Study 28723821 — intervention group
Group type: COMPARATOR
Intervention: Defective wristband
Number of subjects: 179
Study 28723821 — intervention group
Group type: COMPARATOR
Intervention: No wristband
Number of subjects: 179
Study 31052277 — intervention group
Group type: COMPARATOR
Intervention: Permissive underfeeding
Number of subjects: 91
Study 31052277 — intervention group
Group type: COMPARATOR
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 91
Study 31052277 — intervention group
Group type: COMPARATOR
Intervention: Caloric intake
Number of subjects: 91
Study 31052277 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SOFA score and platelets
Number of subjects: 91
Study 31052277 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 91
Study 28381506 — intervention group
Group type: EXPERIMENTAL
Intervention: IV immunoglobulin (IVIg) administered IV at doses of 0.2 or 0.4 g/kg every 2 weeks for 18 months
Number of subjects: 390
Study 28381506 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low‐dose albumin)
Number of subjects: 390
Study 26115520 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional liver transplantation with venovenous bypass
Number of subjects: 32
Study 26115520 — intervention group
Group type: EXPERIMENTAL
Intervention: Piggyback liver transplantation
Number of subjects: 32
Study 23527597 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 315
Study 23527597 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 315
Study 23527597 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 315
Study 23527597 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 315
Study 21450935 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 471
Study 21450935 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight subjects (BMI < 25)
Number of subjects: 471
Study 19366272 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg/day (with option to adjust to 5 or 10 mg/day at weeks 4 and 8)
Number of subjects: 116
Study 19366272 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg/day
Number of subjects: 116
Study 19366272 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg/day (pre-washout)
Number of subjects: 116
Study 19366272 — intervention group
Group type: COMPARATOR
Intervention: No drug (post-washout)
Number of subjects: 116
Study 16393433 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg twice daily for 5 days
Number of subjects: 118
Study 16393433 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 118
Study 14705151 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher risk and higher motivated group
Number of subjects: 78
Study 14705151 — intervention group
Group type: COMPARATOR
Intervention: Combined group
Number of subjects: 78
Study 14705151 — intervention group
Group type: COMPARATOR
Intervention: Lower risk or lower motivated group
Number of subjects: 78
Study 11072552 — intervention group
Group type: EXPERIMENTAL
Intervention: Backrest elevation of 30 degrees
Number of subjects: 8
Study 11072552 — intervention group
Group type: COMPARATOR
Intervention: Flat/horizontal backrest position
Number of subjects: 8
Study 9069297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate plus antacid, diphenhydramine, and viscous lidocaine
Number of subjects: 111
Study 9069297 — intervention group
Group type: COMPARATOR
Intervention: Standard combination of antacid, diphenhydramine, and viscous lidocaine
Number of subjects: 111
Study 8366411 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium for 10 days
Number of subjects: 15
Study 8366411 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 15
Study 2951813 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent
Number of subjects: 20
Study 2951813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31934945 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nurse assignment on the last 2 days of hospitalization
Number of subjects: 18203
Study 30010081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs) treatment (50 min/session, 6 sessions/week, total of 25 sessions)
Number of subjects: 43
Study 30010081 — intervention group
Group type: COMPARATOR
Intervention: Sham PEMFs (control group)
Number of subjects: 43
Study 27764835 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal empathy and touch
Number of subjects: 267
Study 27764835 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal empathy
Number of subjects: 267
Study 27764835 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 267
Study 25092690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 250 mg
Number of subjects: 92
Study 25092690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg
Number of subjects: 92
Study 25092690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750 mg
Number of subjects: 92
Study 25092690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin (250 to 750 mg)
Number of subjects: 92
Study 25092690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin (maximum dose 1,250 mg)
Number of subjects: 92
Study 25092690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Number of subjects: 92
Study 22701296 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in Harmony program (LIH, an 8 lesson cognitive‐behaviorally based program)
Number of subjects: 47
Study 22701296 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational‐Support program (ES, an 8 lesson education program)
Number of subjects: 47
Study 19531688 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention (30 min, 5 days a week, for 6 weeks)
Number of subjects: 97
Study 19531688 — intervention group
Group type: COMPARATOR
Intervention: Social visits (control group, same frequency as walking intervention)
Number of subjects: 97
Study 18478914 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy + NPPV
Number of subjects: 32
Study 18478914 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 32
Study 15157952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal plasma levels of interleukin‐6 (IL‐6)
Number of subjects: 31
Study 15157952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal plasma levels of tumor necrosis factor‐alpha (TNF)
Number of subjects: 31
Study 15157952 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-sleep IL‐6 levels at 23:00 h
Number of subjects: 31
Study 15157952 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐6 levels at 03:00 h
Number of subjects: 31
Study 15157952 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography and blood sampling
Number of subjects: 31
Study 11167475 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflating cuffs with 40% nitrous oxide gas mixture
Number of subjects: 75
Study 9591438 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil cationic protein (ECP) evaluation before, during, and after immunotherapy with pollen or mite allergens (Allergovit or Novo‐Helisen, Nexter, Allergopharma)
Number of subjects: 111
Study 9591438 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total IgE levels
Number of subjects: 111
Study 9591438 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP levels during immunotherapy
Number of subjects: 111
Study 9591438 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without allergic hypersensitivity)
Number of subjects: 111
Study 7887824 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour hemodialysis at high blood flow (400 ml/min)
Number of subjects: 20
Study 7887824 — intervention group
Group type: COMPARATOR
Intervention: 4-hour hemodialysis at low blood flow (200 ml/min)
Number of subjects: 20
Study 7887824 — intervention group
Group type: EXPERIMENTAL
Intervention: High urea elimination during hemodialysis
Number of subjects: 20
Study 7887824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration volume
Number of subjects: 20
Study 7887824 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea removal and ultrafiltration between dialyses
Number of subjects: 20
Study 3348136 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) oral spray
Number of subjects: 9
Study 3348136 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) sublingual tablets
Number of subjects: 9
Study 6105567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin
Number of subjects: 150
Study 6105567 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 150
Study 31058709 — intervention group
Group type: EXPERIMENTAL
Intervention: Berkeley Rudimentary Vision Test (BRVT)
Number of subjects: 50
Study 31058709 — intervention group
Group type: EXPERIMENTAL
Intervention: Freiburg Acuity Test (FrACT)
Number of subjects: 50
Study 31058709 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BRVT and FrACT
Number of subjects: 50
Study 28678044 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for gastrointestinal risk factors and prophylactic proton pump inhibitor (PPI) therapy (pantoprazole 40 mg for 1 year)
Number of subjects: 2009
Study 28678044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening or PPI therapy)
Number of subjects: 2009
Study 26431854 — intervention group
Group type: EXPERIMENTAL
Intervention: TII SCB (16 mL of lidocaine 1.5% with epinephrine 5 µg·mL(‐1) into the largest neural cluster and additional 16 mL divided into equal aliquots injected inside each satellite cluster)
Number of subjects: 40
Study 26431854 — intervention group
Group type: COMPARATOR
Intervention: AXB (5.5 mL around the musculocutaneous nerve and 23.5 mL at the 6 o'clock position of the axillary artery)
Number of subjects: 40
Study 23719518 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral passive accessory mobilization to the symptomatic hand
Number of subjects: 28
Study 23719518 — intervention group
Group type: COMPARATOR
Intervention: Nontherapeutic dose of intermittent ultrasound on the affected side
Number of subjects: 28
Study 20692708 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directedness
Number of subjects: 134
Study 20692708 — intervention group
Group type: EXPERIMENTAL
Intervention: Asceticism
Number of subjects: 134
Study 20692708 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline personality disorder symptoms
Number of subjects: 134
Study 19237882 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (0.01-0.03 units/min)
Number of subjects: 779
Study 19237882 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (5-15 microg/min)
Number of subjects: 779
Study 19237882 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin infusion
Number of subjects: 779
Study 19237882 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 779
Study 17630036 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (capecitabine plus irinotecan and second-line capecitabine plus oxaliplatin)
Number of subjects: 820
Study 17630036 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment (capecitabine, irinotecan, and capecitabine plus oxaliplatin)
Number of subjects: 820
Study 17630036 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment
Number of subjects: 820
Study 17630036 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 820
Study 15450049 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) oral suspension 800 mg/d for 12 weeks
Number of subjects: 0
Study 15450049 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 0
Study 11876454 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental education and use of parents as nursing assistants on ward A
Number of subjects: 1081
Study 11876454 — intervention group
Group type: COMPARATOR
Intervention: No parental assistance on ward B
Number of subjects: 1081
Study 9715363 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 8
Study 9715363 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 8
Study 9715363 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (open maintenance treatment)
Number of subjects: 8
Study 8071282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin (150 mg nightly)
Number of subjects: 579
Study 8071282 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin (150 mg nightly)
Number of subjects: 579
Study 8071282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 579
Study 8071282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 579
Study 8071282 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 579
Study 3195222 — intervention group
Group type: EXPERIMENTAL
Intervention: First series (12 persons) with short clicks; intervals increased from 100 to 500 ms, decreased from 5000 to 100 ms, or varied randomly.
Number of subjects: 42
Study 3195222 — intervention group
Group type: EXPERIMENTAL
Intervention: Second series (24 persons) with short clicks; only regime 3 applied (random order).
Number of subjects: 42
Study 3195222 — intervention group
Group type: EXPERIMENTAL
Intervention: Third series (6 persons) with electrocutaneous stimuli; intervals increased from 100 to 500 ms, decreased from 5000 to 100 ms, or varied randomly.
Number of subjects: 42
Study 786358 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose of phenytoin sodium at 12.00 hours
Number of subjects: 53
Study 786358 — intervention group
Group type: COMPARATOR
Intervention: Two or three spaced doses of phenytoin sodium/day
Number of subjects: 53
Study 30700230 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Web in addition to usual care (n=43)
Number of subjects: 83
Study 30700230 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (control group, n=40)
Number of subjects: 83
Study 28551844 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg on day 1 followed by 100 mg twice daily
Number of subjects: 47
Study 28551844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 28551844 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 47
Study 25307530 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 105
Study 25307530 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight women
Number of subjects: 105
Study 24022373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (PC)
Number of subjects: 50
Study 24022373 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 21967830 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-level incentive
Number of subjects: 125
Study 21967830 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-level incentive
Number of subjects: 125
Study 21967830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physician and group incentives
Number of subjects: 125
Study 21967830 — intervention group
Group type: COMPARATOR
Intervention: No incentives (control)
Number of subjects: 125
Study 19757980 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure therapy (AT)
Number of subjects: 80
Study 17694378 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intraarterial and intramuscular transplantation of autologous mononuclear bone marrow stem cells
Number of subjects: 13
Study 15093755 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium channel antagonists (nifedipine or nicardipine)
Number of subjects: 42
Study 11210250 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDOflash rotary files
Number of subjects: 24
Study 11210250 — intervention group
Group type: COMPARATOR
Intervention: ProFile files (.04, .06 and Orifice Shapers)
Number of subjects: 24
Study 11367652 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium Wilfordii Complex Ester Tablet (TWT), 2 tablets, 3 times a day for 6 weeks
Number of subjects: 277
Study 11367652 — intervention group
Group type: COMPARATOR
Intervention: Tripterygium Wilfordii Polycoside Tablet (TPT), 2 tablets, 3 times a day for 6 weeks
Number of subjects: 277
Study 11367652 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium Wilfordii Complex Ester Tablet (TWT)
Number of subjects: 277
Study 11367652 — intervention group
Group type: COMPARATOR
Intervention: Tripterygium Wilfordii Polycoside Tablet (TPT)
Number of subjects: 277
Study 7889947 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (400 mg single intravenous dose)
Number of subjects: 496
Study 7889947 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole (2 g before and 1 g after surgery)
Number of subjects: 496
Study 3053896 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 8
Study 29254510 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-deployment family violence
Number of subjects: 6711
Study 29254510 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-deployment stranger violence
Number of subjects: 6711
Study 29254510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat role deployment
Number of subjects: 6711
Study 29254510 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic stress disorder symptoms
Number of subjects: 6711
Study 29254510 — intervention group
Group type: EXPERIMENTAL
Intervention: Common mental disorders
Number of subjects: 6711
Study 29254510 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggression
Number of subjects: 6711
Study 29144393 — intervention group
Group type: EXPERIMENTAL
Intervention: HWP‐F (hydrolyzed whey/intact casein =63/37)
Number of subjects: 0
Study 29144393 — intervention group
Group type: EXPERIMENTAL
Intervention: IWP‐F (intact whey/intact casein =61/39)
Number of subjects: 0
Study 29144393 — intervention group
Group type: COMPARATOR
Intervention: BF (breast-fed)
Number of subjects: 0